NDAINHALATIONPOWDER
Approved
May 2013
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1
Data completeness
5/8 — Partial
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BREO ELLIPTA is a fixed-dose combination inhaled powder containing fluticasone furoate (inhaled corticosteroid) and vilanterol (long-acting beta-2 agonist) for maintenance treatment of asthma and COPD. The combination provides anti-inflammatory and bronchodilator effects through dual mechanisms. It was approved by the FDA in May 2013 and represents a key maintenance therapy in respiratory disease management.
$1.4BPart D
PeakStable
4.7 years to LOEBREO ELLIPTA remains at peak commercial performance with $1.4B in annual Part D spending, indicating a mature, large-scale brand requiring significant commercial and supply chain infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study to Evaluate the Therapeutic Equivalence and Safety of Fluticasone Furoate and Vilanterol Inhalation Powder 100 mcg/25 mcg and BREO ELLIPTA 100 mcg/25 mcg in Participants With Asthma
Started Apr 2026
0Respiratory
Why This Matters for Your Career
Worked on BREO ELLIPTA at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.